Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
Portfolio Pulse from Benzinga Newsdesk
Amgen reports positive results from a Phase 3 trial of TEPEZZA for chronic TED, with significant improvement in proptosis. A second trial is ongoing in Japan.
September 24, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's TEPEZZA achieved significant improvement in proptosis in a Phase 3 trial for chronic TED, with 89% of patients showing improvement. A second trial is ongoing in Japan.
The positive results from the Phase 3 trial indicate a strong efficacy of TEPEZZA, which could lead to increased adoption and sales. The ongoing trial in Japan suggests potential for international market expansion. These factors are likely to positively impact Amgen's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90